The present invention provides a method of diagnosing endometriosis and/or infertility in a subject, comprising: a) obtaining a sample from the subject; b) detecting a level of expression of a SIRT1 gene and/or protein in the sample; c) detecting a level of expression of a BCL6 gene and/or protein in the sample; d) comparing the level of expression detected in (b) with the level of expression of a SIRT1 gene and/or protein in a sample obtained from a control subject or a population of control subjects; e) comparing the level of expression detected in (c) with the level of expression of a BCL6 gene and/or protein in a sample obtained from a control subject or a population of control subjects; and f) diagnosing the subject as having infertility when the subject has a level of expression of the SIRT1 gene and/or protein greater than the level of expression of the SIRT1 gene and/or protein of the control subject or population of control subjects and also has a level of expression of the BCL6 gene and/or protein that is greater than the level of expression of the BCL6 gene and/or protein of the control subject or population of control subjects.

The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.

The present invention pertains to methods for characterizing proteins in a sample using native capillary electrophoresis-mass spectrometry. The present invention pertains to methods for detecting and/or discriminating between post-translational modification variants of an antibody of interest in a sample, detecting and/or discriminating between antibodies in an antibody mixture, and characterizing monospecific antibody side products in a bispecific antibody sample.

Provided herein are novel methods for increasing T cell effector function in a T cell populations, as well as methods for increasing T cell effector function in a subject. The methods include contacting a T cell in a T cell population with a pharmaceutical composition comprising an antagonist of histone deacetylase 3 (HDAC3). Also provided herein are methods for identifying a compound that modulates HDAC3 activity in cytotoxic T cells.

Provided is a compound that comprises the structure:

##STR00001##

where SIG is a signaling molecule and R.sup.3 is a formyl, a succinyl, a methyl succinyl, or a myristoyl. Also provided is a kit is provided that comprises the above compound, with instructions for determining the presence of the enzyme. Additionally, a method is provided for determining whether a sample has an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an -amino of a lysine. Also provided is a method of determining whether a molecule inhibits an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an -amino of a lysine.

Disclosed herein is an assay for determining the concentration of p-aminophenol present in a sample. More particularly, the present invention relates to an improvement of an enzyme-based assay for determining the concentration of acetaminophen present in a sample.

Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (NAFLD) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatohepatitis (NASH) are also provided.

The present invention relates to a method of detecting the presence of a bacterial and/or fungal cell in a sample through detecting the presence of nicotinamidase activity or nicotinamidase, wherein the presence of nicotinamidase activity or nicotinamidase indicates the presence of a bacterial and/or fungal cell in the sample. The invention also relates to a method for monitoring bacterial and/or fungal cell contamination in a cell of tissue culture comprising detecting the presence of nicotinamidase activity or nicotinamidase in the cell or tissue culture.

An integrated platform is provided for direct and unbiased label-free native analysis of N-glycans from single cells and biological samples as small as 1 nL or less. An in-capillary sample processing method is coupled with high-sensitivity label-free capillary electrophoresis and mass spectrometry. Direct, label-free characterization and quantification of single-cell surface N-glycomes can be performed with the detection of up to 100 N-glycans per single cell and up to 400 N-glycans per nL of blood. N-glycome alterations can be detected at the single-cell level for diagnosis of medical conditions. The platform also preserves cell integrity and therefore can be used for spatial glycomic and multiomic profiling at the single cell level.

A method for quantitatively determining the amount of acetaminophen in a sample with greater precision, greater sensitivity and fewer interactions and fewer spectral and chemical interferences with other compounds contained in the sample. The method includes acetaminophen being hydrolyzed and the resulting p-aminophenol being reacted with a compound of general formula (III): ##STR00001##
in the presence of an oxidant to form a compound of general formula (IV): ##STR00002##
wherein R1 and R2, independently of one another, are selected from H, CH.sub.3, and OCH.sub.3, R3 is C.sub.2H.sub.5 and R4 is a C.sub.1-4 alkyl moiety with a terminal sulfonate group, with the proviso that at least one of R1 and R2 is OCH.sub.3 and/or R4 additionally has at least one OH substituent, and then the amount of the compound of general formula (IV) in the reaction mixture being photometrically determined.